BG105250A - Means for reducing apoptosis - Google Patents

Means for reducing apoptosis

Info

Publication number
BG105250A
BG105250A BG105250A BG10525001A BG105250A BG 105250 A BG105250 A BG 105250A BG 105250 A BG105250 A BG 105250A BG 10525001 A BG10525001 A BG 10525001A BG 105250 A BG105250 A BG 105250A
Authority
BG
Bulgaria
Prior art keywords
cells
reducing apoptosis
apoptosis
reducing
administered
Prior art date
Application number
BG105250A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michel BRIL Antoine
Robin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Laboratoires Pharmaceutiques S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Laboratoires Pharmaceutiques S.A.S. filed Critical Smithkline Beecham Plc
Publication of BG105250A publication Critical patent/BG105250A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG105250A 1998-07-21 2001-02-14 Means for reducing apoptosis BG105250A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
BG105250A true BG105250A (en) 2001-11-30

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105250A BG105250A (en) 1998-07-21 2001-02-14 Means for reducing apoptosis

Country Status (25)

Country Link
EP (2) EP1098639B1 (de)
JP (1) JP2002521326A (de)
KR (1) KR20010079551A (de)
CN (1) CN1310620A (de)
AP (1) AP2001002036A0 (de)
AT (1) ATE288746T1 (de)
AU (1) AU5053799A (de)
BG (1) BG105250A (de)
BR (1) BR9912117A (de)
CA (1) CA2338211A1 (de)
DE (1) DE69923687T2 (de)
DK (1) DK1098639T3 (de)
EA (1) EA200100165A1 (de)
ES (1) ES2237929T3 (de)
HU (1) HUP0103199A3 (de)
ID (1) ID26986A (de)
IL (1) IL140664A0 (de)
NO (1) NO20010292L (de)
OA (1) OA11579A (de)
PL (1) PL345627A1 (de)
PT (1) PT1098639E (de)
SI (1) SI1098639T1 (de)
SK (1) SK1012001A3 (de)
TR (1) TR200100207T2 (de)
WO (1) WO2000004890A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043007A1 (en) * 1999-01-19 2000-07-27 Sankyo Company, Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
KR20000036035A (ko) * 1996-09-12 2000-06-26 가와무라 요시부미 트로글리타존을 함유하는 글루타티온 환원효소 활성증강제
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
CA2311125C (en) * 1997-11-19 2011-01-18 Takeda Chemical Industries, Ltd. Apoptosis inhibitor
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
ID26986A (id) 2001-02-22
DK1098639T3 (da) 2005-06-13
HUP0103199A3 (en) 2002-08-28
TR200100207T2 (tr) 2001-05-21
SK1012001A3 (en) 2001-08-06
EP1516617A2 (de) 2005-03-23
EA200100165A1 (ru) 2001-08-27
NO20010292L (no) 2001-03-08
BR9912117A (pt) 2001-04-10
HK1037865A1 (en) 2002-02-22
DE69923687T2 (de) 2006-04-06
PL345627A1 (en) 2002-01-02
SI1098639T1 (de) 2005-08-31
OA11579A (en) 2004-06-01
EP1098639B1 (de) 2005-02-09
WO2000004890A1 (en) 2000-02-03
AP2001002036A0 (en) 2001-03-31
ATE288746T1 (de) 2005-02-15
HUP0103199A2 (hu) 2002-05-29
KR20010079551A (ko) 2001-08-22
NO20010292D0 (no) 2001-01-18
AU5053799A (en) 2000-02-14
DE69923687D1 (de) 2005-03-17
IL140664A0 (en) 2002-02-10
CA2338211A1 (en) 2000-02-03
PT1098639E (pt) 2005-06-30
CN1310620A (zh) 2001-08-29
EP1098639A1 (de) 2001-05-16
ES2237929T3 (es) 2005-08-01
JP2002521326A (ja) 2002-07-16

Similar Documents

Publication Publication Date Title
PL341300A1 (en) Non-dissolvable compositions for monitoring glucose level in blood
CY2424B1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
OA08138A (en) Disinfection method and composition therefor.
IL124557A0 (en) Compositions for reducing blood glucose and/or inhibiting the activity of cgrp
PL346520A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
AU1941301A (en) Implantable nickel-free stainless steel stents
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
EP0198092A4 (de) Oberflächlich behandeltes magnesium oder dessen legierungen und verfahren zum oberflächenbehandeln.
GB9311276D0 (en) Well inserts for use in tissue culture
AU4830097A (en) Use of an extract of Cimicifuga
EP0671768A3 (de) Verbesserungen in oder in Bezug auf Elektroden für LSI.
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
MY120530A (en) Combination preparation for use in dementia
GB0210357D0 (en) Methods for regulating blood glucose and appetite suppression in type 2 diabetics
EP0330218A3 (de) Lysyl-Oxidase-Inhibitoren
GB2160892B (en) Fe-cr-al type implant alloy for medical treatment
IL126161A0 (en) Method for treating autism
AP2001002036A0 (en) Use of glucose uptake enhancer for reducing apoptosis.
PL328924A1 (en) Method of treating abuse of substances
EP0904094A4 (de) Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de) Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
BG105251A (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
ZA992400B (en) Process for hot-rolling stainless steel and surface treatment compositions used therein.